论文部分内容阅读
目的观察白细胞介素-2(IL-2)对异基因造血干细胞移植术(allo-HSCT)后白血病早期复发患者的治疗效果。方法 2010年6月～2011年6月,本科共对14例allo-HSCT后复发的患者给予IL-2治疗,观察其临床疗效及并发症。结果 13名患者随访13～24月(中位时间18月),未出现本病全面复发,无病生存率为92.85%。GVHD的表现均为Ⅰ度,发生率为35.7%。结论 IL-2是治疗allo-HSCT后早期复发的有效且重要的方法,取得了较好的疗效,且治疗后GVHD的发生率低、表现较轻。
Objective To observe the therapeutic effect of interleukin-2 (IL-2) on patients with early relapse of leukemia after allo-HSCT. Methods From June 2010 to June 2011, a total of 14 patients with relapsed after allo-HSCT were treated with IL-2. The clinical efficacy and complications were observed. Results Thirteen patients were followed up for 13-24 months (median 18 months). There was no complete recurrence of this disease and the disease-free survival rate was 92.85%. The performance of GVHD were grade Ⅰ, the incidence was 35.7%. Conclusion IL-2 is an effective and important method for early recurrence after allo-HSCT, and has achieved good results. The incidence of GVHD after treatment is low and mild.